

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspal633cxq

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*  
\* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/Caplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	OCT 27	Free display of legal status information in CA/Caplus,
			USPATFULL, and USPAT2 in the month of November.
NEWS EXPRESS	MAY 26 09	CURRENT WINDOWS VERSION IS V8.4,	
		AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.	
NEWS HOURS		STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN		Welcome Banner and News Items	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges

and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:02:35 ON 04 NOV 2009

=> FIL BIOSIS CAPLUS EMBASE  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.22	0.22

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 17:02:47 ON 04 NOV 2009  
Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 17:02:47 ON 04 NOV 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 17:02:47 ON 04 NOV 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> s CSNK or casein kinase  
L1 12343 CSNK OR CASEIN KINASE

=> s l1 and RAC  
L2 41 L1 AND RAC

=> s l2 and antisense  
L3 7 L2 AND ANTISENSE

=> s l3 and PMO  
L4 2 L3 AND PMO

=> dup rem l4  
PROCESSING COMPLETED FOR L4  
L5 2 DUP REM L4 (0 DUPLICATES REMOVED)

=> d bib abs 1-  
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2004:471005 CAPLUS  
DN 141:34681  
TI Human modifier protein MRAC sequence homologs of the RAC pathway  
and use in cancer diagnosis, therapy and drug screening  
IN Kadyk, Lisa C.; Francis, George Ross; Bjerke, Lynn Margaret;  
Lickteig, Kim  
PA Exelixis, Inc., USA  
SO PCT Int. Appl., 62 pp.  
CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 2

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
PI	WO 2004048540	A2	20040610	WO 2003-US37547
20031124				
	WO 2004048540	A3	20070830	
CH, CN,	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,			
GD, GE,	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,			
LC, LK,	GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,			
NO, NZ,	LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI,			
TJ, TM,	OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,			
	TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
AZ, BY,	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			
EE, ES,	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			
SK, TR,	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,			
TD, TG,	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,			
	AP, EA, EP, OA			
CA 2506634	A1	20040610	CA 2003-2506634	
20031124				
CA 2518381	A1	20040610	CA 2003-2518381	
20031124				
AU 2003295884	A1	20040618	AU 2003-295884	
20031124				
EP 1572973	A2	20050914	EP 2003-787097	
20031124				
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,			
MC, PT,	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,			
SK				
JP 2006516097	T	20060622	JP 2004-555681	
20031124				
US 20070142271	A1	20070621	US 2006-535446	
20061031				
PRAI US 2002-428874P	P	20021125		
WO 2003-US37547	W	20031124		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention has designed a genetic screen to identify modifier genes of

RAC pathway that also affect cell migration in C. elegans, where

various specific genes were silenced by RNA inhibition (RNAi) in a ced-10;  
 mig-2 double mutant background. Casein kinase II and neurotropic tyrosine kinase receptor (MRAC) genes were identified as a  
 modifier of the RAC pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, casein kinase (MRAC) genes are attractive drug targets for the treatment of pathologies associated with a defective RAC signaling pathway, such as cancer. The invention provides protein cDNA sequences of novel  
 human orthologs of casein kinase (MRAC) genes. The invention also provides methods for utilizing these RAC pathway modifier genes and polypeptides to identify candidate therapeutic agents  
 that can be used in the treatment of disorders associated with defective RAC pathway.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2004:471003 CAPLUS  
 DN 141:34679  
 TI Human casein kinase protein sequence homologs (CSNKs)  
 as modifiers of the RAC pathway and use in cancer diagnosis,  
 therapy and drug screening  
 IN Kadyk, Lisa C.; Francis, George Ross; Bjerke, Lynn Margaret  
 PA Exelixis, Inc., USA  
 SO PCT Int. Appl., 53 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

DATE	PATENT NO.	KIND	DATE	APPLICATION NO.
-----	-----	----	-----	-----
PI	WO 2004048538	A2	20040610	WO 2003-US37545
20031124	WO 2004048538	A3	20071115	
CH, CN,	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,			
GD, GE,	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,			
LC, LK,	GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,			
NO, NZ,	LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI,			
TJ, TM,	OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,			
	TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
AZ, BY,	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			

EE, ES, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 SK, TR, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,  
 TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,

AP, EA, EP, OA  
 AU 2003295882 A1 20040618 AU 2003-295882  
 20031124  
 EP 1578941 A2 20050928 EP 2003-787095  
 20031124

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,  
 MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU,  
 SK

JP 2006516096 T 20060622 JP 2004-555679  
 20031124  
 US 20070141664 A1 20070621 US 2003-535445  
 20031124  
 PRAI US 2002-428874P P 20021125  
 WO 2003-US37545 W 20031124

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention has designed a genetic screen to identify modifier genes of

RAC pathway that also affect cell migration in C. elegans, where various specific genes were silenced by RNA inhibition (RNAi) in a ced-10;

and mig-2 double mutant background. Casein kinase (CSNK) gene was identified as a modifier of the RAC pathway. Accordingly, vertebrate orthologs of these modifiers,

preferably the human orthologs, casein kinase (CSNK) genes are attractive drug targets for the treatment of pathologies associated with a defective RAC signaling pathway, such

as cancer. The invention provides protein cDNA sequences of novel human orthologs of casein kinase (CSNK) genes.

The invention also provides methods for utilizing these RAC pathway modifier genes and polypeptides to identify candidate therapeutic

agents that can be used in the treatment of disorders associated with defective RAC pathway.

=>

---Logging off of STN---

=>  
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	22.75	22.97
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.64	
-1.64		

STN INTERNATIONAL LOGOFF AT 17:04:07 ON 04 NOV 2009